Medical
Biotechnology
Pharmaceutical

Progenics Pharmaceuticals

$5.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.32%) As of 12:51 PM EDT today
-$0.02 (-0.32%) Today

Why Robinhood?

You can buy or sell PGNX and other stocks, options, ETFs, and crypto commission-free!

About PGNX

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. Read More The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Employees
79
Headquarters
New York, New York
Founded
1986
Market Cap
444.69M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
691.94K
High Today
$5.34
Low Today
$5.17
Open Price
$5.32
Volume
258.48K
52 Week High
$9.42
52 Week Low
$3.62

Collections

Medical
Biotechnology
Pharmaceutical
Cancer Prevention
Therapy
Health
Technology

PGNX Earnings

-$0.23
-$0.16
-$0.08
-$0.01
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 30, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.